AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer

AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

AstraZeneca and Merck said an ovarian cancer treatment failed in Phase 3 testing on Thursday — leading AZN stock and MRK stock to tumble. Pharma stocks broadly fell amid coronavirus worries.

Pharma Giants Hit The Skids After Ovarian Cancer Treatment Flops

The company is divesting most of its global commercial rights to a suite of five medications.

AstraZeneca Sells Hypertension Drugs in $350 Million Deal

Teva Pharmaceutical

The FDA says that China's COVID-19 containment efforts have led one pharmaceutical company to warn of a looming supply-chain problem.

Coronavirus Disruptions in China Beginning to Affect U.S. Drug Supplies

RedHill to promote Movantik® in the U.S. upon closing        Movantik® generated U.S. net sales of $96 million in 2019     Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing  

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

Shares of the pharmaceutical giant are down 4.3% in light of the news.

AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance

AstraZeneca's (AZN) CEO Pascal Soriot on Q4 2019 Results - Earnings Call Transcript

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AstraZeneca forecast a likely slowdown in revenue growth this year, assuming a hit from China's coronavirus epidemic lasting up to a few months, although it added there had been limited disruption to its operations so far.

AstraZeneca braces for coronavirus hit, but no impact so far

Abbott Labs

Bristol-Myers

Eli Lilly

Novartis

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

Pfizer

Raymond James

Analysts at investment bank Raymond James theorize that the trend will continue.

Analysis: Major Pharmaceuticals' January Drug Price Hikes Were Smallest in at Least 6 Years

iShares MSCI United Kingdom ETF

Vodafone Group

The U.K.'s departure from the EU has many traders wondering where prices are headed. These charts suggest a potential move higher.

3 UK Charts to Watch

Strong late-stage clinical trial results are helping bolster this blood thinner's appeal.

AstraZeneca's Brilinta Beats Aspirin in Trial for Reducing Stroke Chances

AbbVie

Allergan

Nestle SA

U.S. drugmaker AbbVie's  $63 billion tie-up with Allergan  is getting help from Nestle  and AstraZeneca  buying up products the Irish-domiciled company is shedding to placate regulators.

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

Aethlon Medical

Alpha Pro Tech

BioCryst Pharmaceuticals

Cleveland BioLabs

Cerus

Co-Diagnostics

Inovio Pharmaceuticals

Lakeland Industries

Moderna

NanoViricides

Novavax

Vir Biotechnology

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

Despite the company's best efforts, England's top regulators say the drug is too expensive.

England Officially Rejects AstraZeneca's Lung Cancer Drug

Alexion Pharma

Amgen

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

The blockbuster drug is already approved for three other types of tumors.

AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer

AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.

AstraZeneca Announces Positive FDA Updates on Cancer Drugs

Two AstraZeneca  cancer drugs received orphan status for treatment of liver cancer, a designation that may eventually speed progress to approval. The U.S. Food and Drug Administration granted the special.

AstraZeneca Treatments Win Orphan FDA Status In Liver Cancer

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

AstraZeneca to End Phase III Study on Fish Oil Heart Drug

Amarin Corporation Plc

Acasti Pharma

Shares of Amarin Corp. PLC AMRN, +4.80% rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular events in patients with high triglyceride levels reported disappointing trial results.

Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint

AstraZeneca's Latest FDA Approval Provides Hope For Pancreatic Cancer Patients

Johnson & Johnson

Sanofi

Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.

AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA

News for AstraZeneca Stock (AZN)